AVPT vs PLAB

The Advanced Deterministic Scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. Despite solid revenue growth (23.6% YoY) and strong gross margins (74.51%), profitability remains thin with only a 0.50% net margin and weak ROE (0.67%). Analysts recommend a 'buy' with a $19.02 target, implying 51% upside, but insider selling of $89.11M over the last six months contradicts this optimism. The stock trades at a high forward P/E of 32.18, above sector averages, while recent price performance is bearish (-31.3% over 1Y), reflecting market skepticism despite improving earnings trends.

PLAB presents a dichotomy between a pristine balance sheet and concerning valuation/sentiment signals. While the Piotroski F-Score of 4/9 indicates stable health and the company maintains zero debt with exceptional liquidity, the stock's 157.8% one-year rally has outpaced its modest 6-8% growth rates. The current price of $45.84 is trading near its growth-based intrinsic value ($47.27) but significantly above its defensive Graham Number ($33.13). Heavy insider selling by the CEO and President, coupled with a high PEG ratio of 2.64, suggests the stock is currently overextended.